{"id":84937,"date":"2026-04-27T15:34:13","date_gmt":"2026-04-27T15:34:13","guid":{"rendered":"https:\/\/www.merckconnect.ca\/en\/?post_type=mhh-sticky-footer&#038;p=84937"},"modified":"2026-04-29T14:10:14","modified_gmt":"2026-04-29T14:10:14","slug":"biomarker-testing","status":"publish","type":"mhh-sticky-footer","link":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/","title":{"rendered":"biomarker testing"},"content":{"rendered":"<div class=\"mhh-sticky-footer-panel mhh-sticky-footer-panel--05f33a7439a5aa7ecfd61d74104ac577\">\n    <button class=\"mhh-sticky-footer-panel__expand-button\" \n            data-event-name=\"accordion_click\" \n            data-design-module=\"indication\"\n            data-design-category=\"accordion\"\n            data-design-label=\"expand\">\n                    <svg\n            xmlns=\"http:\/\/www.w3.org\/2000\/svg\"\n            fill=\"currentColor\"\n            viewBox=\"0 0 16 16\"\n            >\n            <path\n            d=\"M8 4a.5.5 0 0 1 .5.5v3h3a.5.5 0 0 1 0 1h-3v3a.5.5 0 0 1-1 0v-3h-3a.5.5 0 0 1 0-1h3v-3A.5.5 0 0 1 8 4z\"\/>\n            <\/svg>\n                <span>EXPAND<\/span>\n        <\/button>\n    <div class=\"mhh-sticky-footer-inner\">\n    \n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-text-color has-link-color has-object-object-font-size wp-elements-f5481f378e6b9c23df4795c855aa663b   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--101f8d92b954d34124086a6e2b790310\" style=\"color:#2c6d3c\"><img loading=\"lazy\" decoding=\"async\" width=\"210\" height=\"210\" class=\"wp-image-85033\" style=\"width: 60px\" src=\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png\" alt=\"Image\" srcset=\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png 210w, https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png?resize=150,150 150w, https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png?resize=120,120 120w\" sizes=\"auto, (max-width: 210px) 100vw, 210px\" \/>Important KEYTRUDA\u00ae safety information<\/p>\n\n    <\/div>\n<\/div>\n\n\n<div class=\"mhh-sticky-footer-expanded-panel mhh-sticky-footer-expanded-panel--f50bf3832e14000c7dbe72662d79e6cc \" dir=\"ltr\">\n    <div class=\"mhh-sticky-footer-expanded-panel__inner\">\n        <div class=\"mhh-sticky-footer-expanded-panel__close-button-wrapper\">\n            <button class=\"mhh-sticky-footer-expanded-panel__close-button\">\n                        <svg\n                xmlns=\"http:\/\/www.w3.org\/2000\/svg\"\n                fill=\"currentColor\"\n                viewBox=\"0 0 16 16\"\n            >\n                <path\n                d=\"M4.646 4.646a.5.5 0 0 1 .708 0L8 7.293l2.646-2.647a.5.5 0 0 1 .708.708L8.707 8l2.647 2.646a.5.5 0 0 1-.708.708L8 8.707l-2.646 2.647a.5.5 0 0 1-.708-.708L7.293 8 4.646 5.354a.5.5 0 0 1 0-.708z\"\/>\n            <\/svg>\n                                    <\/button>\n        <\/div>\n        <div class=\"mhh-sticky-footer-expanded-panel__body\">\n            \n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-text-color has-link-color has-object-object-font-size wp-elements-f5481f378e6b9c23df4795c855aa663b   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--101f8d92b954d34124086a6e2b790310\" style=\"color:#2c6d3c\"><img loading=\"lazy\" decoding=\"async\" width=\"210\" height=\"210\" class=\"wp-image-85033\" style=\"width: 60px\" src=\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png\" alt=\"Image\" srcset=\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png 210w, https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png?resize=150,150 150w, https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png?resize=120,120 120w\" sizes=\"auto, (max-width: 210px) 100vw, 210px\" \/>Important KEYTRUDA\u00ae safety information<\/p>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--f0b6104db98cd8c0f947682a3a3a01b1 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--bf0c96db0e13c6f81dfa30922e4af58b mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--190aebb47fe1373fec5d9d4be86c3c0f\"><strong>KEYTRUDA\u00ae has been issued marketing authorization&nbsp;<mark style=\"background-color:#6cc04a\" class=\"has-inline-color\">with conditions,<\/mark>&nbsp;pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. KEYTRUDA\u00ae is indicated for the treatment of:<\/strong><\/p>\n\n\n\n<p class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--9c11bec07f98a0ece5bc042ab9b658c3\"><strong>cHL (classical Hodgkin Lymphoma)<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--018c2e6b6f2fe1c9bf92082b1606dafd mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    As monotherapy, for the treatment of adult and pediatric patients with refractory or relapsed cHL who have failed ASCT (autologous stem cell transplant), or who are not candidates for multi-agent salvage chemotherapy and ASCT; an improvement in overall survival has not yet been established    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--b53329be82f1cde47cafdc61142e8d89\"><strong>PMBCL (primary mediastinal B-cell lymphoma)<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--4d7eca5153e76dd678b3d92c67b1f13d mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    As monotherapy, for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more lines of therapy; an improvement in survival or disease-related symptoms has not been established    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ca58428013c71abd2d65efb5f18f3d53\"><strong>UC (urothelial carcinoma)<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--1992495fc7ab5711da377f86cffb85c8 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    For the treatment of adult patients with BCG (Bacillus Calmette-Guerin)-unresponsive, high-risk, NMIBC (non-muscle invasive bladder cancer) with CIS (carcinoma in-situ) with or without papillary tumours who are ineligible for or have elected not to undergo cystectomy. The indication is authorized based on tumour complete response rate and durability of response    <\/li>\n\n<\/ul>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-object-object-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a09146dd68adb84623941e23f9f75f4d\"><strong>KEYTRUDA\u00ae has been issued marketing authorization&nbsp;<mark style=\"background-color:#006ead\" class=\"has-inline-color has-white-color\">without conditions<\/mark>&nbsp;for:<\/strong><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-object-object-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--242a1940ad0c2aa5cc1431f52073d20e\"><strong>HNSCC (head and neck squamous cell carcinoma)<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--d9fb542aa3c4cd55a12e8a7c443baaa8 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    For the treatment of adult patients with resectable locally advanced HNSCC whose tumours express PD-L1 ([CPS] \u2265 1), as determined by a validated test, as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    For the first-line treatment of metastatic or unresectable recurrent HNSCC as monotherapy, in adult patients whose tumours have PD-L1 expression (CPS \u2265 1) as determined by a validated test    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    For the first-line treatment of metastatic or unresectable recurrent HNSCC in combination with platinum and FU (fluorouracil) chemotherapy, in adult patients.    <\/li>\n\n<\/ul>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-object-object-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--104c26ba5c480537a1e2eea34ab5747b\"><strong>TNBC (triple-negative breast cancer)<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--bbeb48f3b55c609d3adc8192336785c6 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with chemotherapy, for the treatment of adult patients with locally recurrent unresectable or metastatic TNBC, who have not received prior chemotherapy for metastatic disease and whose tumours express PD-L1 (CPS \u2265 10) as determined by a validated test. Consult the description of the study for the chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine\/carboplatin) and dosing regimens used    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    For the treatment of adult patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery. Consult the description of the study for the chemotherapy regimen (carboplatin and paclitaxel, followed by doxorubicin or epirubicin and cyclophosphamide) used    <\/li>\n\n<\/ul>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-object-object-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--3e2919f6785e0c7c1cc032399a758328\"><strong>NSCLC (non-small cell lung carcinoma)<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--1ab2491d817825a85c196c6894008783 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    For the first-line treatment, as monotherapy, of adult patients with metastatic NSCLC or stage III disease where patients are not candidates for surgical resection or definitive chemoradiation, expressing PD-L1 (TPS \u2265 1%) as determined by a validated test, with no EGFR or ALK genomic tumour aberrations. A positive association was observed between the level of PD-L1 expression and the magnitude of the treatment benefit.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with pemetrexed and platinum chemotherapy, for the treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with carboplatin and either paclitaxel or nab-paclitaxel, for the treatment of adult patients with metastatic squamous NSCLC with no prior systemic chemotherapy treatment for metastatic NSCLC.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    As monotherapy, for the treatment of adult patients with metastatic NSCLC whose tumours express PD-L1 (TPS \u2265 1%) as determined by a validated test and who have disease progression on or after platinum-containing chemotherapy; patients with EGFR or ALK genomic tumour aberrations should have received an authorized therapy for these aberrations prior to receiving KEYTRUDA\u00ae.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    As monotherapy, for the adjuvant treatment of adult patients with Stage IB (T2a \u22654\u00a0cm), II, or IIIA NSCLC who have undergone complete resection and platinum-based chemotherapy    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with platinum-containing chemotherapy, for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) NSCLC, as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery    <\/li>\n\n<\/ul>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-object-object-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--405abb32d77e2e11c4a93def57e7e469\"><strong><strong>MPM (malignant pleural mesothelioma)<\/strong><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--88ad12172e2078a8f7364c90d4c1e2df mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic MPM    <\/li>\n\n<\/ul>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-object-object-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f5f4b9cf4899abd9288d9bcefe52dcd0\"><strong>UC (urothelial carcinoma)<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--a887ec951f91ed01f31e9dc609035512 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with enfortumab vedotin, for the treatment of adult patients with unresectable locally advanced or metastatic UC (mUC) with no prior systemic therapy for mUC    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    For the treatment of adult patients with locally advanced unresectable or mUC, as monotherapy, who are not eligible for any platinum-containing chemotherapy. An improvement in survival or disease-related symptoms has not been established    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    For the treatment of adult patients with locally advanced or mUC, as monotherapy, who have disease progression during or following platinum-containing chemotherapy or within 12 months of completing neoadjuvant or adjuvant platinum-containing chemotherapy    <\/li>\n\n<\/ul>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-object-object-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--fd93549d8ea95a13d580b34373cecbca\"><strong>Cervical cancer<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--d6cf1b47fa731d36b95f92e97b0e2d2f mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with chemoradiotherapy (CRT), for treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS \u2265 1) as determined by a validated test.    <\/li>\n\n<\/ul>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-object-object-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f0c18b3beb3f15d135744292711baa26\"><strong>Melanoma<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--9b8e2dda3624b85f79437205b8f377e0 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    For the treatment of adult patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab; subjects with BRAF V600 mutant melanoma may have received prior BRAF inhibitor therapy.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    For the treatment of adult patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    For the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection    <\/li>\n\n<\/ul>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-object-object-font-size   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ebf7d7a1b505f76072080e0b1b27e61e\"><strong>RCC (renal cell carcinoma)<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--e191413673034ea6dfc250b9b9113b8c mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with axitinib, for the treatment of adult patients with advanced or metastatic RCC with no prior systemic therapy for metastatic RCC.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with lenvatinib, for the treatment of adult patients with advanced (not amenable to curative surgery or radiation) or metastatic RCC with no prior systemic therapy for metastatic RCC.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    As monotherapy, for the adjuvant treatment of adult patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.    <\/li>\n\n<\/ul>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--636bd37037a2d81058fcbd102f55d832\"><strong>CRC (colorectal cancer)<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--487de7b157a2df7d95821d8a70c625b4 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    As monotherapy, for the treatment of adult patients with metastatic MSI-H (microsatellite instability high cancer) or dMMR (mismatch repair deficient) CRC as determined by a validated test    <\/li>\n\n<\/ul>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--41800d281440427d38ad0d36a103bb6e\"><strong>Endometrial carcinoma<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--2eb95f865d96b644f26788e758f888b4 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with carboplatin and paclitaxel, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, and then continued as monotherapy    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.    <\/li>\n\n<\/ul>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--9b7c98ad90e38ae90bbe6856747e2c40\"><strong>Esophageal cancer<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--2eb8174a2668208bc579a41036432ac1 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with platinum and fluoropyrimidine based chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic carcinoma of the esophagus.    <\/li>\n\n<\/ul>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--90286e2645ab95cb852d211bc62b79b4\"><strong><strong>Gastric cancer or GEJ (gastroesophageal junction) adenocarcinoma<\/strong><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--7c4becda46ff4946c2c3bfa456f070a9 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    In combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours express PD-L1 (CPS \u2265 1) as determined by a validated test.    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    in combination with fluoropyrimidine- and platinum-containing chemotherapy,for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.    <\/li>\n\n<\/ul>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--9b84f7bc7db04762ce765ade1136c160\"><strong><strong>MSI-H (microsatellite instability high) or mismatch repair deficient (dMMR) cancer<\/strong><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--19019ebaae9571221bf379e22990e6b7 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    As monotherapy, for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumours, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options    <\/li>\n\n<\/ul>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--e47edc7548c9ec2a343d54e3adeb4627\"><strong>BTC (biliary tract cancer)<\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--aa5dd4848180b6aed5b8d3b1e6b61ca8 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    For the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma (BTC), in combination with gemcitabine-based chemotherapy    <\/li>\n\n<\/ul>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--49d1fb22469ad84ddd2ea116a01404f7\"><strong><strong>Important safety information&nbsp;<\/strong><\/strong><\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color wp-elements-846be03be8beacdcae5856a03a83b4b8   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c3938fa56d202b67eadb16bc2f61d90e\" style=\"color:#2c6d3c\"><span style=\"text-decoration: underline\"><strong>Clinical use:<\/strong><\/span><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--97fc78367f632fce3bb08a70487d271b\">The safety and efficacy of KEYTRUDA\u00ae has not been established for pediatric patients with conditions other than melanoma (Stage IIB, IIC, or III), relapsed or refractory cHL, relapsed or refractory PMBCL, or unresectable or metastatic MSI-H or dMMR solid tumours.&nbsp;<\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--48ab31199f3997cd76853b741286b488\">Geriatrics (\u226565 years of age): No overall differences in safety or efficacy were reported between elderly patients (65 years and over) and younger patients (less than 65 years) for KEYTRUDA\u00ae monotherapy. No overall differences in efficacy were reported between elderly patients (65 years and over) and younger patients (less than 65 years) for KEYTRUDA\u00ae combination therapy. Limited safety and efficacy information is available for KEYTRUDA\u00ae in cHL \u226565 years of age (n=20).&nbsp;&nbsp;<\/p>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color wp-elements-8d8380ee31da0f038375886c53ab7bf3   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--7c793140169980a5b065f7db5b3ef2f6\" style=\"color:#2c6d3c\"><span style=\"text-decoration: underline\"><strong>Relevant warnings and precautions:<\/strong><\/span><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--fa80951289cb3540195d03a58b018825 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Immune-mediated adverse reactions, including severe and fatal cases:    \n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--52bc3602f15e5895b6f74552ec4dbce9 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-line\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Immune-mediated adverse reactions, including severe and fatal cases:    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Pneumonitis    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Colitis    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Hepatitis    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Nephritis and renal dysfunction    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Endocrinopathies including adrenal insufficiency, hypophysitis, type 1 diabetes mellitus, and thyroid disorders    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis    <\/li>\n\n<\/ul>\n\n<\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Other immune-mediated adverse events including uveitis, arthritis, myositis, encephalitis, sarcoidosis, myasthenic syndrome\/myasthenia gravis, vasculitis, Guillain-Barr\u00e9 syndrome, hemolytic anemia, pancreatitis, myelitis, hypoparathyroidism, gastritis, pericarditis, myocarditis, sclerosing cholangitis, aplastic anemia, and exocrine pancreatic insufficiency    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Solid organ transplant rejection    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Use in combination with axitinib for RCC    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Use with thalidomide analogue and dexamethasone in multiple myeloma    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Allogeneic stem cell transplant after and before treatment    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Severe infusion-related reactions    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Teratogenic toxicity    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Women of childbearing potential should use highly effective contraception and take active measures to avoid pregnancy during treatment and for at least 4 months after the last dose\u00a0\u00a0    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Advise women not to breastfeed during treatment and for at least 4 months after the last dose\u00a0\u00a0    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Patients with hepatic impairment\u00a0     <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Renal impairment    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Driving and operating machinery    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Monitoring requirements    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Pediatrics    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Geriatrics    <\/li>\n\n<\/ul>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--4160272b7b502f589d5a18d6020b4ccf mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--210f0b96aaf2dd94ecfbca57b1936e93 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-11 mhh-mcn-column--l-12\">\n    \n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color wp-elements-b6c3a09fac60a7d422971625e8d3f27b   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--893204e7d7c2784eee7f3bbbd3ff2df8\" style=\"color:#2c6d3c\"><strong><strong>For more information:<\/strong><\/strong><\/p>\n\n\n\n<p class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color  has-link-color mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--6e7538af95f23172fb13353137d025a8\">Consult the KEYTRUDA\u00ae <a href=\"http:\/\/www.merck.ca\/en\/wp-content\/uploads\/sites\/20\/2021\/04\/KEYTRUDA-PM_E.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Product Monograph<\/a>&nbsp;for important information regarding adverse reactions, drug interactions, and dosing information that has not been discussed in this piece. The Product Monograph is also available by calling us at 1-800-567-2594 or by email at medinfocanada@merck.com.&nbsp;<\/p>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--fe88004c7374b193115d38361d2cb284\">ALK=anaplastic lymphoma kinase; BRAF=B-raf proto-oncogene; CPS=combined positive score; EGFR=epidermal growth factor receptor; HER2=human epidermal growth factor receptor 2; MEK=mitogen-activated protein\/extracellular signal-regulated kinase; PD-L1=programmed death ligand 1; TPS=tumour proportion score.&nbsp;&nbsp;<\/p>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--f279dcf193b60e355df99dd9cbefba61\"><\/p>\n\n        <\/div>\n    <\/div>\n<\/div>\n\n\n\n<div class=\"mhh-sticky-footer-safety-content\">\n    <\/div>\n","protected":false},"template":"","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"promomats_ca_generated_at":0,"promomats_ca_screen_sizes":["Desktop","Mobile"],"footnotes":""},"mh-depends-on":[],"class_list":["post-84937","mhh-sticky-footer","type-mhh-sticky-footer","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>biomarker testing | Merck Connect Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"biomarker testing | Merck Connect Canada\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck Connect Canada\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-29T14:10:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png\" \/>\n\t<meta property=\"og:image:width\" content=\"210\" \/>\n\t<meta property=\"og:image:height\" content=\"210\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/\",\"name\":\"biomarker testing | Merck Connect Canada\",\"isPartOf\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png\",\"datePublished\":\"2026-04-27T15:34:13+00:00\",\"dateModified\":\"2026-04-29T14:10:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/#primaryimage\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png\",\"contentUrl\":\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png\",\"width\":210,\"height\":210,\"caption\":\"Image\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.merckconnect.ca\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"biomarker testing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#website\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/\",\"name\":\"Merck Connect Canada\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.merckconnect.ca\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#organization\",\"name\":\"Merck Connect Canada\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png\",\"contentUrl\":\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png\",\"width\":1284,\"height\":331,\"caption\":\"Merck Connect Canada\"},\"image\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"biomarker testing | Merck Connect Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/","og_locale":"en_US","og_type":"article","og_title":"biomarker testing | Merck Connect Canada","og_url":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/","og_site_name":"Merck Connect Canada","article_modified_time":"2026-04-29T14:10:14+00:00","og_image":[{"width":210,"height":210,"url":"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png","type":"image\/png"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/","url":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/","name":"biomarker testing | Merck Connect Canada","isPartOf":{"@id":"https:\/\/www.merckconnect.ca\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/#primaryimage"},"image":{"@id":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png","datePublished":"2026-04-27T15:34:13+00:00","dateModified":"2026-04-29T14:10:14+00:00","breadcrumb":{"@id":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/#primaryimage","url":"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png","contentUrl":"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2026\/04\/Frame-144.png","width":210,"height":210,"caption":"Image"},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/biomarker-testing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckconnect.ca\/en\/"},{"@type":"ListItem","position":2,"name":"biomarker testing"}]},{"@type":"WebSite","@id":"https:\/\/www.merckconnect.ca\/en\/#website","url":"https:\/\/www.merckconnect.ca\/en\/","name":"Merck Connect Canada","description":"","publisher":{"@id":"https:\/\/www.merckconnect.ca\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckconnect.ca\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.merckconnect.ca\/en\/#organization","name":"Merck Connect Canada","url":"https:\/\/www.merckconnect.ca\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png","contentUrl":"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png","width":1284,"height":331,"caption":"Merck Connect Canada"},"image":{"@id":"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer\/84937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer"}],"about":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/types\/mhh-sticky-footer"}],"version-history":[{"count":6,"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer\/84937\/revisions"}],"predecessor-version":[{"id":85066,"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer\/84937\/revisions\/85066"}],"wp:attachment":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/media?parent=84937"}],"wp:term":[{"taxonomy":"mh-depends-on","embeddable":true,"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mh-depends-on?post=84937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}